
COMPLETION OF THE PROPOSED ACQUISITION OF THE TRANCHE 2 SALE SHARES OF 17% OF THE ISSUED AND PAID-UP ORDINARY SHARE CAPITAL IN ARDENCE PHARMA SDN BHD

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in Company's announcements dated 17 October 2023 and 8 November 2023 ("**Announcements**").*

The board of directors (the "**Board**" or "**Directors**") of the Company refers to the Announcements relating to the Proposed Acquisition and is pleased to announce that the Tranche 2 Completion has taken place on 9 May 2025. Accordingly, subsequent to the Tranche 2 Completion, the latest shareholding held by the Group in Ardence Pharma is 82%.

The total consideration for the Tranche 2 Sale Shares ("**Tranche 2 Purchase Price**") shall be **RM10,887,718.79** (or equivalent to approximately S\$3.35 million at the exchange rate of S\$1.00: RM3.25), subject to adjustments as prescribed under the SPAs and described in paragraph 3.3 of the announcement dated 17 October 2023.

The Company will make further announcements to keep shareholders informed, as and when there are further material developments on the Proposed Acquisition in due course.

BY ORDER OF THE BOARD

Lim See Wah

Executive Chairman and Chief Executive Officer

9 May 2025

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) who can be contacted at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.